Q2 2024 Earnings Estimate for Sanofi Issued By Leerink Partnrs (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) – Equities researchers at Leerink Partnrs cut their Q2 2024 earnings estimates for Sanofi in a report released on Tuesday, April 16th. Leerink Partnrs analyst D. Risinger now expects that the company will earn $0.91 per share for the quarter, down from their previous forecast of $0.93. The consensus estimate for Sanofi’s current full-year earnings is $4.15 per share. Leerink Partnrs also issued estimates for Sanofi’s Q3 2024 earnings at $1.30 EPS, Q4 2024 earnings at $0.82 EPS, FY2026 earnings at $4.78 EPS and FY2027 earnings at $5.00 EPS.

Several other research analysts also recently commented on the stock. TheStreet downgraded shares of Sanofi from a “b” rating to a “c” rating in a research note on Friday, February 9th. Morgan Stanley initiated coverage on Sanofi in a research report on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 price objective on the stock. Finally, StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 27th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $55.00.

Sanofi Stock Performance

Shares of SNY stock opened at $46.30 on Friday. The company has a market capitalization of $117.12 billion, a P/E ratio of 19.62, a PEG ratio of 1.72 and a beta of 0.61. Sanofi has a fifty-two week low of $42.63 and a fifty-two week high of $57.82. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.27. The stock has a 50 day moving average price of $47.52 and a two-hundred day moving average price of $48.62.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, February 1st. The company reported $0.89 earnings per share for the quarter, missing the consensus estimate of $0.94 by ($0.05). Sanofi had a net margin of 12.56% and a return on equity of 27.47%. The company had revenue of $11.76 billion for the quarter, compared to analysts’ expectations of $13.02 billion.

Institutional Investors Weigh In On Sanofi

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Rise Advisors LLC lifted its position in Sanofi by 98.4% during the fourth quarter. Rise Advisors LLC now owns 506 shares of the company’s stock valued at $25,000 after buying an additional 251 shares during the period. SRS Capital Advisors Inc. boosted its stake in Sanofi by 289.1% during the first quarter. SRS Capital Advisors Inc. now owns 463 shares of the company’s stock worth $25,000 after acquiring an additional 344 shares in the last quarter. Householder Group Estate & Retirement Specialist LLC purchased a new stake in Sanofi in the third quarter worth about $26,000. Fairfield Bush & CO. bought a new position in shares of Sanofi during the first quarter valued at approximately $26,000. Finally, Salem Investment Counselors Inc. purchased a new position in shares of Sanofi during the fourth quarter valued at approximately $27,000. 10.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Increases Dividend

The company also recently announced an annual dividend, which will be paid on Thursday, June 6th. Shareholders of record on Friday, May 10th will be issued a dividend of $1.478 per share. This is an increase from Sanofi’s previous annual dividend of $1.38. The ex-dividend date is Thursday, May 9th. This represents a dividend yield of 2.98%. Sanofi’s dividend payout ratio is 58.47%.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.